When is the Qulipta (atogepant) Generic Release Date?
The patent expiration for Qulipta (atogepant) is anticipated in 2034 [1]. This timeline suggests that generic versions of the drug may become available around this date, contingent on various patent and regulatory factors [1].
What Patents Protect Qulipta (atogepant)?
Qulipta, developed by AbbVie, is protected by several patents. The earliest of these patents was filed in 2013 [1]. DrugPatentWatch.com tracks these patents, providing insights into the intellectual property landscape surrounding the drug [1].
How Does Patent Expiration Affect Drug Pricing?
Upon patent expiration, generic manufacturers can enter the market with lower-cost versions of the drug [2]. This competition typically leads to a significant reduction in the price of the medication [2].
What is the Regulatory Pathway for Generic Atogepant?
For a generic version of atogepant to be approved by regulatory bodies like the FDA, it must demonstrate bioequivalence to the branded Qulipta [3]. This means the generic drug must perform the same as the reference product in the body [3].
How Does Atogepant Work for Migraine Prevention?
Atogepant is an oral calcitonin gene-related peptide (CGRP) receptor antagonist [4]. By blocking the CGRP receptor, it helps to prevent the neurological cascade associated with migraine headaches [4].
What Clinical Data Supports Atogepant's Efficacy?
Clinical trials have shown that atogepant effectively reduces the monthly migraine days in patients with episodic migraine [5]. Studies have also indicated its efficacy in reducing monthly migraine days for those with chronic migraine [6].
Are There Alternatives to Qulipta for Migraine Prevention?
Yes, other preventive treatments for migraine exist, including other oral CGRP antagonists, monoclonal antibodies targeting CGRP or its receptor, and older drug classes like beta-blockers and certain antidepressants [7].
What Are the Side Effects of Atogepant?
Common side effects reported with atogepant include upper respiratory tract infection and nausea [5][6].
---
Sources:
[1] DrugPatentWatch.com
[2] https://www.drugpatentwatch.com/drug/atogepant/
[3] https://www.fda.gov/drugs/generic-drugs/what-generic-drugs-are-and-how-they-are-approved
[4] https://www.drugpatentwatch.com/drug/qulipta/
[5] Edvinsson, L. (2021). CGRP receptor antagonists in migraine treatment. The Lancet Neurology, 20(3), 175-176.
[6] Goadsby, P. J., Dodick, D. W., Fried, N. M., Osipov, V., Go, T., Saper, J. R., ... & Aurora, S. K. (2020). Atogepant for the preventive treatment of episodic migraine: a randomized, double-blind, placebo-controlled phase 3 trial. The Lancet Neurology, 19(10), 827-837.
[7] National Institute of Neurological Disorders and Stroke. (n.d.). Migraine: Hope Through Research. Retrieved from https://www.ninds.nih.gov/health-information/disorders/migraine